Literature DB >> 22232540

Transformative mutation specific pharmacotherapy for cystic fibrosis.

Don B Sanders, Philip M Farrell.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22232540     DOI: 10.1136/bmj.e79

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  A potentiator induces conformational changes on the recombinant CFTR nucleotide binding domains in solution.

Authors:  Elena Galfrè; Lauretta Galeno; Oscar Moran
Journal:  Cell Mol Life Sci       Date:  2012-07-03       Impact factor: 9.261

2.  Risk factors for the progression of cystic fibrosis lung disease throughout childhood.

Authors:  Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell
Journal:  Ann Am Thorac Soc       Date:  2014-01

Review 3.  Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?

Authors:  Beth K Potter; Sara D Khangura; Kylie Tingley; Pranesh Chakraborty; Julian Little
Journal:  Genet Med       Date:  2015-04-09       Impact factor: 8.822

4.  Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.

Authors:  Joseph F Levy; Marjorie A Rosenberg; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2016-10-14

5.  In vivo readout of CFTR function: ratiometric measurement of CFTR-dependent secretion by individual, identifiable human sweat glands.

Authors:  Jeffrey J Wine; Jessica E Char; Jonathan Chen; Hyung-Ju Cho; Colleen Dunn; Eric Frisbee; Nam Soo Joo; Carlos Milla; Sara E Modlin; Il-Ho Park; Ewart A C Thomas; Kim V Tran; Rohan Verma; Marlene H Wolfe
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.